Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Primary Antiphospholipid Syndrome
NCT05671757Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in antiphospholipid syndrome (APS) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Dose Limiting Toxicity at 9 weeks. Started May 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT05671757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671757.